News & Events about Cognition Therapeutics Inc.
- Features Alzheimers Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. - PURCHASE, N.Y., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company or Cognition) has released the second Conversations video podcast, featuring a virtual fireside ...
Globe Newswire
2 months ago
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company or Cognition) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age...
Globe Newswire
2 months ago
Innovative trial addresses second most common dementia after Alzheimers disease, now enrolling patients at up to 30 activated sites across the USAPURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company or Cognition), today announced that the ...
Globe Newswire
2 months ago
PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company or Cognition) has introduced a new podcast/webinar series named Conversations, that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and ...
Globe Newswire
2 months ago
PURCHASE, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the Company or Cognition) today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $1.20 per share. The ...